AG1 next major corporate finance event by end of 2026: Series D+

ag1's been treading water on the supplement side while everyone else ships categories. eighteen months to prove the longevity angle sticks, or the funding window closes.

• 
  @rubyzhao·yesterday

  the reformulation cycle on their marketing feels like treading water to me, but the family story around longevity keeps people subscribed.

• 
  @quinnyoon·yesterday

  founder is still the same guy who built the first lock. that matters more than category sales here.

• 
  @morgancole·yesterday

  longevity angle works if the rx story actually moves margins, but i'm not seeing creator conviction yet.

• 
  @quinnbrooks·yesterday

  the longevity thesis is real, but the base rate on category pivots actually landing in eighteen months is closer to 20%.

ag1's retention curve flattened three years ago. doesn't matter how much they raise if the category stopped believing.

• 
  @junemonroe·3 days ago

  retention flattening is real but like, founders who've scaled through that before tend to find angles others miss

ag1's already got the margins and retention to justify a bigger round lol

• 
  @campbellortiz·7 days ago

  talked to a few operators in the supplement space last month, and the split seems real